PSA screening: determinants of primary-care physician practice patterns

G E Tasian; M R Cooperberg; M B Potter; J E Cowan; K L Greene; P R Carroll; J M Chan

doi:10.1038/pcan.2011.59

journal article Nov 29, 2011

PSA screening: determinants of primary-care physician practice patterns

G E Tasian M R Cooperberg M B Potter J E Cowan K L Greene P R Carroll J M Chan

Prostate Cancer and Prostatic Diseases Vol. 15 No. 2 pp. 189-194 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/pcan.2011.59

Topics

No keywords indexed for this article. Browse by subject →

References

23

[1]

Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J . Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626–631. 10.1001/jama.1995.03530080042039

[2]

Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2010; 29: 228–234. 10.1200/jco.2010.31.4252

[3]

Dall'Era MA, Carroll PR . Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol 2009; 19: 258–262. 10.1097/mou.0b013e328329eba3

[4]

Screening and Prostate-Cancer Mortality in a Randomized European Study

Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol et al.

New England Journal of Medicine 2009 10.1056/nejmoa0810084

[5]

Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319. 10.1056/nejmoa0810696

[6]

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232–2241. 10.1016/j.juro.2009.07.093

[7]

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70–98. 10.3322/caac.20066

[8]

Lin K, Lipsitz R, Miller T, Janakiraman S . Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive services task force. Ann Intern Med 2008; 149: 192–199. 10.7326/0003-4819-149-3-200808050-00009

[9]

Kish L . Survey Sampling. John Wiley & Sons, New York, NY, 1995.

[10]

Tasian GE, Yiee JH, Copp HL . Imaging use and cryptorchidism: determinants of practice patterns. J Urol 2011; 185: 1882–1887. 10.1016/j.juro.2010.12.065

[11]

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–224. 10.1056/nejmoa030660

[12]

Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA et al. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol; e-pub ahead of print 25 August 2010.

[13]

Hall IJ, Taylor YJ, Ross LE, Richardson LC, Richards TB, Rim SH . Discussions about prostate cancer screening between US. Primary care physicians and their patients. J Gen Intern Med 2011; 26: 1098–1104. 10.1007/s11606-011-1682-0

[14]

Harris R, Lohr KN . Screening for prostate cancer: an update of the evidence for the US Preventive services task force. Ann Intern Med 2002; 137: 917–929. 10.7326/0003-4819-137-11-200212030-00014

[15]

Kim HL, Benson DA, Stern SD, Gerber GS . Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey. Urology 2002; 59: 266–271. 10.1016/s0090-4295(01)01504-7

[16]

Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW . Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011; 103: 520–523. 10.1093/jnci/djr007

[17]

Hamilton RJ, Kahwati LC, Kinsinger LS . Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 2164–2171. 10.1158/1055-9965.epi-10-0082

[18]

Berrow D, Humphrey C, Hayward J . Understanding the relation between research and clinical policy: a study of clinicians' views. Qual Health Care 1997; 6: 181–186. 10.1136/qshc.6.4.181

[19]

Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–1984. 10.1056/nejmoa043739

[20]

Screening for prostate cancer. US Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185–191. 10.7326/0003-4819-149-3-200808050-00008

[21]

Wilt TJ . The VA/NCI/AHRQ CSP#407: Prostate Cancer Intervention Versus Observation Trial (PIVOT): main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. American Urological Associan Annual Meeting, May 17, 2011, Washington, DC. 10.1093/jncimonographs/lgs041

[22]

Cull WL, O'Connor KG, Sharp S, Tang SF . Response rates and response bias for 50 surveys of pediatricians. Health Serv Res 2005; 40: 213–226. 10.1111/j.1475-6773.2005.00350.x

[23]

Response rates to mail surveys published in medical journals

David A. Asch, M.Kathryn Jedrziewski, Nicholas A. Christakis

Journal of Clinical Epidemiology 1997 10.1016/s0895-4356(97)00126-1

Cited By

23

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA

Katherine Fleshner, Sigrid V. Carlsson · 2016

Nature Reviews Urology

Metrics

23

Citations

23

References

Details

Published: Nov 29, 2011
Vol/Issue: 15(2)
Pages: 189-194
License: View

Authors

Cite This Article

G E Tasian, M R Cooperberg, M B Potter, et al. (2011). PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer and Prostatic Diseases, 15(2), 189-194. https://doi.org/10.1038/pcan.2011.59

PSA screening: determinants of primary-care physician practice patterns

You May Also Like